BCTG Acquisition Corp.
Completed 2021-08-10- CIK 1819133
- BCTG
- Now TNGX
- IPO 2020-09-04
- $167M trust
- 420 filings
Successfully merged with Tango Therapeutics, Inc. • Now trading as TNGX
- IPO Size
- $167M
- raised at the IPO
- Trust
- $167M
- as of 2021-06-30
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2020
- year it listed
Filings, by quarter
420 filings over 26 quarters; violet bars carry a milestone
- 20 Q3: 19 filings
- 20 Q4: 4 filings
- 21 Q1: 3 filings
- 21 Q2: 10 filings
- 21 Q3: 32 filings
- 21 Q4: 10 filings
- 22 Q1: 15 filings
- 22 Q2: 13 filings
- 22 Q3: 10 filings
- 22 Q4: 6 filings
- 23 Q1: 13 filings
- 23 Q2: 12 filings
- 23 Q3: 17 filings
- 23 Q4: 13 filings
- 24 Q1: 17 filings
- 24 Q2: 19 filings
- 24 Q3: 32 filings
- 24 Q4: 18 filings
- 25 Q1: 14 filings
- 25 Q2: 18 filings
- 25 Q3: 19 filings
- 25 Q4: 20 filings
- 26 Q1: 27 filings
- 26 Q2: 40 filings
- 26 Q3: 18 filings
- 26 Q4: 1 filing
- S-1 filed 20 Q3
- IPO 20 Q3
- Definitive agreement 21 Q2
- Completed 21 Q3
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
BCTG Acquisition Corp. is a blank-check company seeking to complete a merger or other business combination. It intends to focus on innovative biotechnology companies in North America and Europe.
Investment Focus
Biopharmaceuticals
Geographic Focus
North America, Europe
Key Information
As the filings state it
- IPO Date
- 2020-09-04
- Total Redemptions
- $11.1M
- PIPE
- $186M
- Jurisdiction of Incorporation
- Delaware
- SIC
- 6770
- Completion Date
- 2021-08-10
- Merger Target
- Tango Therapeutics, Inc.
- SPAC Ticker
- BCTG
- Merged Ticker
- TNGX
Stock Performance
TNGXTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2020-09-04 | $10.33 | |
| At Merger | 2021-08-11 | $9.99 | -3% |
| 6 Months Post-Merger | 2022-02-10 | $9.38 | -6% |
| 1 Year Post-Merger | 2022-08-11 | $5.10 | -49% |
| 2 Years Post-Merger | 2023-08-11 | $7.51 | -25% |
| Current Price | 2026-10-14 | $22.19 | +115% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The team draws on Boxer Capital, a private biopharmaceutical investment firm with experience investing in therapeutics, including targeted oncology, and includes company founders with biotechnology investing backgrounds plus directors with expertise in oncology drug discovery, development, regulation and company leadership.